They needed the CR to cover the 45-60day lag in receipts.
At 2000 patients a month increasing even at 50-100% per month, it’ll still take 2-3 qtrs to cover cash costs.
On these figures given by BOT, the monthly revenue growth doesn’t really kick in to $20mill plus until H2 2025 CY. Add the 45-60 day payment cycle, BOT basically now have about $85 mill to cover until the Dec qtr.
$45-48 mill wasn’t going to last 3 qtrs with the rising cost of doing business.. Instos saw that, and the market correction helped make their job easier.. IMO.
Ann: Botanix $40 Million Capital Raising for Sofdra Rollout, page-145
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $632.3M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.0¢ | 31.5¢ | $1.477M | 4.593M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 460000 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 362852 | 15 |
View Market Depth
| Last trade - 14.31pm 27/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |